2016 ACR/ARHP Annual Meeting

November 11-16, 2016. Washington, DC.

View by Number View by Title View Sessions

View by Date

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

Abstract Number: 8L

A Randomized, Double-Blind, Placebo-Controlled Study of Bimagrumab in Patients with Sporadic Inclusion Body Myositis
Abstract Number: 638

A Randomized, Open-Label, Single-Dose, Parallel-Group Trial to Determine the Pharmacokinetics, Safety and Immunogenicity of GP2017, a Proposed Adalimumab Biosimilar, Following a Single Subcutaneous Injection By an Autoinjector or Prefilled Syringe in Healthy Male Subjects
Abstract Number: 71

A Rare Coding Allele in IFIH1 is Protective for Psoriatic Arthritis
Abstract Number: 2250

A Real World View of Rheumatoid Arthritis Patients Treated with Advanced Therapies: Comparing Patient Profiles and Outcomes
Abstract Number: 1206

A Replication Study and Meta-Analysis Demonstrate the Influence of the mtDNA Haplogroups in the Rate of Incident Knee Osteoarthritis. Functional Explanation of This Association Using Transmitochondrial Cybrids
Abstract Number: 27

A Rheumatologist’s Assessment of Therapy Responses (Rxresp) and Rheumatoid Factor Status (neg/pos) in 1995 Predicted Mortality through 2015 in a Community-Based Cohort of Incident Rheumatoid Arthritis Cases and Matched Control Subjects
Abstract Number: 3034

A Selective JAK1 Inhibitor, Filgotinib Suppresses Lymphocytic Infiltration in Salivary Gland of Non Obese Diabetic Mice Via Suppression of BAFF and Chemokine Production of Salivary Gland Epithelial Cells
Abstract Number: 524

A Self-Determination Theory Based Intervention to Increase Levels of Cardiorespiratory Fitness, Self-Determined Motivation, Physical Activity and Improve Health Outcomes Among Patients Living with Rheumatoid Arthritis
Abstract Number: 3106

A Simple Test for Assessing and Monitoring SLE Disease Activity Status
Abstract Number: 391

A Single Centre Experience from India on the Safety and Efficacy of Cipla Etanercept and Intas Etanercept and Its Comparison with Reference Etanercept(Enbrel) in Children with JIA
Abstract Number: 3028

A Single Infusion of Rituximab Delays the Onset of Arthritis in Subjects at High Risk of Developing RA
Abstract Number: 60

A Single Nucleotide Polymorphism of IL6-Receptor Is Associated with Response to Tocilizumab in Rheumatoid Arthritis: Results from Toci and ROC Studies
Abstract Number: 777

a Singlecenter Experience of Rituximab Treatment in 86 Patients with Systemic Lupus Erythematosus
Abstract Number: 2143

A Small Molecule, SM04690, Has Inhibitory Effects on the Wnt Pathway and Inflammation in Vitro, with Potential Implications for the Treatment of Osteoarthritis
Abstract Number: 122

A Small Number of Patients with SLE Account for Most of the Direct and Indirect Hospitalization Costs

« Previous Page
1
…
5
6
7
8
9
…
219
Next Page »

Jump to: [View All] • a b c d e f g h i j k l m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].